Core Viewpoint - The company, Dirui Medical, is facing challenges in its stock performance and investor relations, with a need for clearer communication and concrete measures to improve its market position and operational efficiency [2][3]. Group 1: Stock Performance - As of January 15, 2026, Dirui Medical's stock closed at 13.61 yuan, down 1.16%, with a turnover rate of 1.21% and a trading volume of 32,800 shares, amounting to a transaction value of 44.77 million yuan [1]. - On the same day, there was a net outflow of 5.39 million yuan from institutional investors, while retail investors saw a net inflow of 4.26 million yuan [4][5]. Group 2: Investor Relations and Company Strategy - The company has a collaboration with Peking Union Medical College Hospital focused on technical research in urine and other fields, but specific progress updates are limited to periodic reports [2]. - Investors have expressed concerns regarding the company's operational strategies and the effectiveness of its various departments, suggesting a need for restructuring to enhance performance [2][3]. - There is a call for the company to take decisive actions such as share buybacks and acquisitions in advanced assets to improve its market standing and implement a dual-track operational strategy [3].